Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Biopharma Stocks Suffer Tough First Quarter

publication date: Apr 1, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China biopharma stocks listed on US exchanges weathered a difficult first quarter of 2008. The ChinaBio® Stock Index fell from 1675 to 1215 during the three months, a substantial decline of 27.4%. China suffered an even more negative quarter. The Shanghai Composite, which had climbed from 1,000 to over 6,000 in two years, peaked in October. Since that time, it dropped below 3,500. In the first quarter of 2008, it watched 34% of its value vaporize as it slid from 5261 to 3472. More details...

Stock Symbols: (AMEX: PJG) (NYSE: MR) (NYSE: WX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners